Novel Psychopharmacologic Interventions in Oncology
* You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
In this presentation, Dr. Christian Bjerre Real discusses the evidence surrounding the use of cannabinoids, canabis, ketamine, MDMA, and psilocybin as an aspect of oncologic treatment. He then uses the research findings to discuss possible mechanisms of action for these treatments, escpecially as pertains to pschedelics.
This Menninger Department of Psychiatry and Behavioral Sciences Grand Rounds session took place on Wednesday, October 19, 2022 at 11:30 a.m. and has been approved for Social Work Credit.
Activity Information
How to Claim Credit
You may claim credit after watching this activity.
You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
Needs Statement
Psychiatrists, psychologists, psychiatric nurses, social workers, and healthcare professionals in related disciplines need to receive regular updates on advances in neuroscience, psychiatric research, psychotherapy, and the evolving best practices for evaluating, diagnosing, and treating psychiatric disorders. The series aims to improve clinical practice through critical appraisal of psychiatric research, the use of evidence-based treatment approaches, and the integration of multiple treatment modalities to enhance the quality of psychiatric care and improve patient outcomes.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Recognize that patients with cancer are using psychopharmacologic drugs such as cannabinoids/cannabis, ketamine, MDMA (3,4-methylenedioxymethamphetamine), and psilocybin to manage their psychological and physical symptoms.
- List the most common reasons why patients with cancer use cannabis.
- Outline the U.S. Food and Drug Administration indications for cannabis use in patients with cancer.
- Describe two currently researched indications for psilocybin-assisted psychotherapy.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Nurses
- Other Health Professionals
Specialties
- Psychiatry
Interest Groups
- Ethics
Activity Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.
Educational Methods
- Lectures
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Social Work: Baylor College of Medicine, Division of Continuing Professional Development (License Number 7270) is an approved continuing education provider for Social Workers through the Texas State Board of Social Worker Examiners. This activity has been approved for 0.75 continuing education unit.
Activity Director
-
Kim-Lan Tran Czelusta, M.D.
Vice Chair for Education, Brown Foundation Chair in Psychiatric Education in the Department of Psychiatry and Behavioral Sciences
Baylor College of Medicine
Term of Approval
October 1, 2022 through October 31, 2024. Original release date: October 1, 2024.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Christian Bjerre Real, M.D., M.M.C.I.
Psychiatrist
New York City, New York
Disclosure:
Nothing to disclose.
Activity Director
-
Kim-Lan Tran Czelusta, M.D.
Vice Chair for Education, Brown Foundation Chair in Psychiatric Education in the Department of Psychiatry and Behavioral Sciences
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Planning Committee Members
-
Kim-Lan Tran Czelusta, M.D.
Vice Chair for Education, Brown Foundation Chair in Psychiatric Education in the Department of Psychiatry and Behavioral Sciences
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Mauro A. Garcia-Altieri, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Wayne Goodman, M.D.
D.C. and Irene Ellwood Chair in Psychiatry
Baylor College of Medicine
Disclosure:
- Research Support: Biohaven Pharmaceuticals
- Intellectual Property (patent rights, royalty payments): Nview
- Consultancy: Biohaven Pharmaceuticals
-
Michael McClam, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Jose Ribas Roca, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Daryl Shorter, M.D.
Associate Professor, Medical Director of Addiction Services
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: